Prospective Evaluation of the Long-term Effectiveness of the Femtosecond Laser-assisted Arcuate Incisions
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02164994|
Recruitment Status : Unknown
Verified April 2015 by Technolas Perfect Vision GmbH.
Recruitment status was: Recruiting
First Posted : June 17, 2014
Last Update Posted : April 24, 2015
|Condition or disease|
The purpose of this prospective post-market-clinical-follow-up study is to address the long-term effectiveness of arcuate incisions, in eyes after VICTUS femtosecond laser-assisted astigmatic keratotomy.
This study will be conducted at Gemini eye clinic in Zlin, Czech Republic by Dr. Pavel Stodulka who will examine up to 100 eyes who previously received VICTUS femtolaser-assisted arcuate incisions treatment.
Patients will be recruited according to the study inclusion/exclusion criteria.
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||Prospective Evaluation of the Long-term (18 Months) Effectiveness of the Femtosecond Laser-assisted Arcuate Incisions Following Cataract Surgery|
|Study Start Date :||April 2014|
|Estimated Primary Completion Date :||September 2015|
|Estimated Study Completion Date :||November 2015|
- Postoperative keratometric cylinder [ Time Frame: 18 months after the VICTUS femtosecond laser-assisted arcuate incisions. ]Postoperative Astigmatism (keratometry) ≤ 1.0 D in 60% of eyes
- Postoperative Manifest Cylinder [ Time Frame: 19 months after VICTUS femtosecond laser-assisted arcuate incisions treatment. ]Postoperative Manifest Astigmatism (manifest refraction) ≤ 1.0 D in 60% of eyes
- Postoperative Objective Cylinder [ Time Frame: 18 months after VICTUS femtosecond laser-assisted arcuate incisions treatment. ]Postoperative Objective Astigmatism (manifest refraction) ≤ 1.0 D in 60% of eyes
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02164994
|Contact: Pavel Stodulka, Dr. med, PhDfirstname.lastname@example.org|
|Gemini Eye Clinic||Recruiting|
|Zlin, Czech Republic, 76001|
|Contact: Pavel Stodulka, Dr. med, PhD +420734575158 email@example.com|
|Contact: Eliška Bařinková +420734575158 firstname.lastname@example.org|
|Principal Investigator: Pavel Stodulka, Dr. med, PhD|
|Principal Investigator:||Pavel Stodulka, Dr. med, PhD||Gemini clinic, Zlin Pavel Stodulka, Dr. med Study Principal Investigator Gemini eye clinic|